港股异动 | 信达生物(01801)午后涨超4% 达伯乐®关键研究长期随访数据于AACR年会公布

智通财经04-24

智通财经APP获悉，信达生物(01801)午后涨超4%，截至发稿，涨3.73%，报86.1港元，成交额6.25亿港元。

消息面上，据信达生物官微消息，近日，新一代ROS1酪氨酸激酶抑制剂达伯乐®(己二酸他雷替尼胶囊，Taletrectinib)关键研究长期随访数据在2026美国癌症研究协会年会(AACR)上以口头报告和壁报形式发布。对TRUST-I和TRUST-II临床试验的长期汇总数据分析显示，TKI初治患者mDOR(中位持续缓解时间)近50个月，mPFS(中位无进展生存期)达46.1个月，ORR(客观缓解率)达89.8%。

达伯乐^®是一种口服、强效、具有中枢神经系统活性、高选择性的新一代ROS1抑制剂。目前，经过NMPA及FDA优先审评和突破性疗法认定，他雷替尼已在中国大陆、中国澳门、美国、日本等多地获批上市。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2629892564?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-24 13:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629892564","market":"hk","top_or_hot":-1,"title":"港股异动 | 信达生物(01801)午后涨超4% 达伯乐®关键研究长期随访数据于AACR年会公布","media":"智通财经","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/01801\">信达生物</a>(01801)午后涨超4%，截至发稿，涨3.73%，报86.1港元，成交额6.25亿港元。</p><p>消息面上，据信达生物官微消息，近日，新一代ROS1酪氨酸激酶抑制剂达伯乐®(己二酸他雷替尼胶囊，Taletrectinib)关键研究长期随访数据在2026美国癌症研究协会年会(AACR)上以口头报告和壁报形式发布。对TRUST-I和TRUST-II临床试验的长期汇总数据分析显示，TKI初治患者mDOR(中位持续缓解时间)近50个月，mPFS(中位无进展生存期)达46.1个月，ORR(客观缓解率)达89.8%。</p><p><span leaf=\"\">达伯乐</span><span><sup><span leaf=\"\">®</span></sup></span><span leaf=\"\">是一种口服、强效、具有中枢神经系统活性、高选择性的新一代ROS1抑制剂。目前，经过NMPA及FDA优先审评和突破性疗法认定，他雷替尼已在中国大陆、中国澳门、美国、日本等多地获批上市。</span></p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 信达生物(01801)午后涨超4% 达伯乐®关键研究长期随访数据于AACR年会公布</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 信达生物(01801)午后涨超4% 达伯乐®关键研究长期随访数据于AACR年会公布\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/01801\">信达生物</a>(01801)午后涨超4%，截至发稿，涨3.73%，报86.1港元，成交额6.25亿港元。</p><p>消息面上，据信达生物官微消息，近日，新一代ROS1酪氨酸激酶抑制剂达伯乐®(己二酸他雷替尼胶囊，Taletrectinib)关键研究长期随访数据在2026美国癌症研究协会年会(AACR)上以口头报告和壁报形式发布。对TRUST-I和TRUST-II临床试验的长期汇总数据分析显示，TKI初治患者mDOR(中位持续缓解时间)近50个月，mPFS(中位无进展生存期)达46.1个月，ORR(客观缓解率)达89.8%。</p><p><span leaf=\"\">达伯乐</span><span><sup><span leaf=\"\">®</span></sup></span><span leaf=\"\">是一种口服、强效、具有中枢神经系统活性、高选择性的新一代ROS1抑制剂。目前，经过NMPA及FDA优先审评和突破性疗法认定，他雷替尼已在中国大陆、中国澳门、美国、日本等多地获批上市。</span></p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1433246.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1433246.html","article_id":"2629892564","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629892564","pubTimestamp":1777009279,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，信达生物午后涨超4%，截至发稿，涨3.73%，报86.1港元，成交额6.25亿港元。消息面上，据信达生物官微消息，近日，新一代ROS1酪氨酸激酶抑制剂达伯乐关键研究长期随访数据在2026美国癌症研究协会年会上以口头报告和壁报形式发布。达伯乐是一种口服、强效、具有中枢神经系统活性、高选择性的新一代ROS1抑制剂。目前，经过NMPA及FDA优先审评和突破性疗法认定，他雷替尼已在中国大陆、中国澳门、美国、日本等多地获批上市。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1589":"北水核心资产","BK4588":"碎股","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","BK1161":"生物科技","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","VXUS":"国际股票ETF-Vanguard","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK4585":"ETF&股票定投概念","01801":"信达生物","BK1583":"高瓴概念","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC"},"translate_title":"Hong Kong stock changes | Innovent Biotech (01801) rose more than 4% in the afternoon Dabole ® Long-term follow-up data of pivotal studies announced at the AACR annual meeting","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1.5,"01801":1.5},"content_text":"智通财经APP获悉，信达生物(01801)午后涨超4%，截至发稿，涨3.73%，报86.1港元，成交额6.25亿港元。消息面上，据信达生物官微消息，近日，新一代ROS1酪氨酸激酶抑制剂达伯乐®(己二酸他雷替尼胶囊，Taletrectinib)关键研究长期随访数据在2026美国癌症研究协会年会(AACR)上以口头报告和壁报形式发布。对TRUST-I和TRUST-II临床试验的长期汇总数据分析显示，TKI初治患者mDOR(中位持续缓解时间)近50个月，mPFS(中位无进展生存期)达46.1个月，ORR(客观缓解率)达89.8%。达伯乐®是一种口服、强效、具有中枢神经系统活性、高选择性的新一代ROS1抑制剂。目前，经过NMPA及FDA优先审评和突破性疗法认定，他雷替尼已在中国大陆、中国澳门、美国、日本等多地获批上市。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629892564","isCrawlerRequest":true}